Results 31 to 40 of about 48,364 (325)

A study on indices of apixaban anticoagulation: A single-center prospective study

Journal of Pharmacological Sciences, 2018
Background: Depending on the characteristics of patients, the blood concentration of apixaban can unexpectedly increase, possibly leading to bleeding events.
Maki Komiyama, Yusuke Miyazaki, Hiromichi Wada, Moritake Iguchi, Mitsuru Abe, Hisashi Ogawa, Masaharu Akao, Hajime Yamakage, Noriko Satoh-Asahara, Yoichi Sunagawa, Tatsuya Morimoto, Koji Hasegawa   +11 more
doaj   +1 more source

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

Journal of the American Medical Association (JAMA), 2021
Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial fibrillation, is uncertain.
W. Ray, C. Chung, C. Stein, W. Smalley, E. Zimmerman, W. Dupont, A. Hung, J. Daugherty, A. Dickson, K. Murray   +9 more
semanticscholar   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Critical Care, 2022
Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding.
O. S. Costa, S. Connolly, Mukul Sharma, J. Beyer-Westendorf, M. Christoph, B. Lovelace, C. Coleman   +6 more
semanticscholar   +1 more source

Critical Analysis of Apixaban Dose Adjustment Criteria

Clinical and Applied Thrombosis/Hemostasis, 2021
Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE).
Anh Vu PharmD, Tao T. Qu PharmD, Rachel Ryu PharmD, BCPS, Shuktika Nandkeolyar MD, Alan Jacobson MD, Lisa T. Hong PharmD, BCPS   +5 more
doaj   +1 more source

Update on Extended Treatment for Venous Thromboembolism [PDF]

, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge, Demelo-Rodríguez, Pablo, Llamazares-Mendo, Cristina, Marra, Alberto M, Peñaloza-Martínez, Eduardo, Proietti, Marco, Soria Fernández-Llamazares, Guillermo, Álvarez-Sala Walther, Luis   +7 more
core   +2 more sources

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Blood Advances, 2021
Key Points The primary outcome, stroke, occurred in 6 of 23 patients randomized to apixaban compared with 0 of 25 patients randomized to warfarin. This study with limitations suggests that apixaban is not an equitable substitute for warfarin to prevent ...
S. Woller, S. Stevens, David A Kaplan, Tzu‐Fei Wang, D. Branch, Danielle Groat, E. Wilson, Brent P. Armbruster, V. Aston, J. Lloyd, M. Rondina, C. Elliott   +11 more
semanticscholar   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources